Orme I M, Roberts A D, Furney S K, Skinner P S
Department of Microbiology, Colorado State University, Fort Collins 80523, USA.
Eur J Clin Microbiol Infect Dis. 1994 Nov;13(11):994-9. doi: 10.1007/BF02111500.
Emerging problems with the treatment of infections caused by Mycobacterium avium and Mycobacterium tuberculosis require the development of new models, both in vitro and in vivo, in which new chemotherapeutic and immunotherapeutic approaches can be tested. In this brief review, the use of cell culture models, in which drugs can be tested for their capacity to inhibit mycobacterial growth within the infected host macrophage, and new models in vivo in which drugs and/or cytokines can be tested in infected mice are discussed. In this latter case, new emerging mouse models include animals with engineered gene disruptions, in which severely disseminated infections can be produced, thus mimicking events in severely immunocompromised human patients.
鸟分枝杆菌和结核分枝杆菌引起的感染治疗中出现的新问题,需要开发新的体外和体内模型,以便测试新的化疗和免疫治疗方法。在这篇简短的综述中,讨论了细胞培养模型(可在其中测试药物抑制受感染宿主巨噬细胞内分枝杆菌生长的能力)以及体内新模型(可在受感染小鼠中测试药物和/或细胞因子)的应用。在后一种情况下,新出现的小鼠模型包括具有工程基因破坏的动物,在这些动物中可产生严重播散性感染,从而模拟严重免疫受损人类患者的情况。